Paraganglioma: Rare Neuroendocrine Tumors Outside the Adrenal Gland
When 28-year-old Arjun noticed a small, painless lump on the side of his neck that gradually grew larger over several months, he initially ignored it thinking it was just a swollen lymph node from a cold. But when the lump reached the size of a lime and he started experiencing pulsating sounds in his ear matching his heartbeat, his doctor ordered imaging tests. The scans revealed a highly vascular tumor wrapped around his carotid artery—a paraganglioma, a rare tumor arising from specialized nerve tissue outside the adrenal glands. Paragangliomas affect only 2-8 people per million each year, making them extremely rare, but understanding these tumors is crucial because they often occur in critical locations near major blood vessels and nerves, and about 40% are hereditary, meaning family members may also be at risk.
What Are Paraganglia and Where Do These Tumors Grow?
Your body contains tiny clusters of specialized nerve cells called paraganglia scattered along major blood vessels from your head to your pelvis. These clusters are part of the sympathetic and parasympathetic nervous systems—the networks controlling automatic body functions you don’t consciously think about, like heart rate, blood pressure, and digestion. Paraganglia originated from the same embryonic tissue (neural crest cells) that forms your nervous system and adrenal glands during fetal development. Their normal job is monitoring oxygen and carbon dioxide levels in your blood and helping regulate blood pressure and blood flow to critical organs.
Paragangliomas are tumors that develop from these paraganglia clusters. When the exact same type of tumor grows in the adrenal gland (sitting on top of the kidneys), doctors call it pheochromocytoma. When it grows anywhere else in the body from paraganglia tissue, it’s called paraganglioma. Think of them as cousins in the same tumor family—both arise from similar cells, both can produce hormones, but they grow in different locations requiring different treatment approaches. About 80-85% of these tumors arise in the adrenal gland (pheochromocytomas) while 15-20% develop outside the adrenal glands as paragangliomas.
Paragangliomas are classified by location into two main groups. Head and neck paragangliomas (about 65% of all paragangliomas) grow along nerves and blood vessels in the neck, skull base, and ear. The most common locations include carotid body tumors (at the fork where the carotid artery splits in the neck), glomus jugulare tumors (in the bone at the skull base near the jugular vein), glomus tympanicum tumors (in the middle ear behind the eardrum), and glomus vagale tumors (along the vagus nerve in the neck). Sympathetic paragangliomas (about 35%) develop in the chest, abdomen, or pelvis along the sympathetic nerve chain running beside the spine. These chest and abdominal paragangliomas behave more like pheochromocytomas—they often produce hormones causing high blood pressure and other symptoms.
The tumors vary greatly in size from less than 1 centimeter (smaller than a pea) to over 10 centimeters (larger than an orange). Most paragangliomas are benign, meaning they don’t spread to other organs, but they cause problems by growing in critical locations near major blood vessels, nerves, and the brain. They are highly vascular tumors—containing many blood vessels—which makes them appear bright red during surgery and creates the characteristic “vascular blush” on imaging scans. About 10-40% of paragangliomas are malignant (cancerous), with higher malignancy rates in sympathetic paragangliomas (15-35%) compared to head and neck paragangliomas (5-10%).
Symptoms Depend on Location and Hormone Production
The symptoms of paraganglioma depend entirely on two factors—where the tumor is located and whether it produces hormones. Head and neck paragangliomas typically don’t produce hormones, so symptoms come purely from the tumor’s size and location pressing on surrounding structures. Carotid body tumors present as a painless, slowly growing neck mass that you or your doctor can feel, pulsatile tinnitus (hearing your heartbeat or whooshing sound in your ear), hoarseness if the tumor presses on the nerve controlling your voice box, and difficulty swallowing if it compresses your esophagus. These tumors are often called “potatoes” by surgeons because they feel like a firm potato under the skin that moves side-to-side but not up-and-down when pushed.
Glomus jugulare and glomus tympanicum tumors grow in or near the ear causing very specific symptoms: pulsatile tinnitus (most common symptom—hearing rhythmic pulsing, whooshing, or roaring in one ear), hearing loss (progressive difficulty hearing on the affected side), ear fullness or pressure sensation, reddish mass visible behind the eardrum if the tumor is in the middle ear, facial nerve weakness causing drooping on one side of the face, and dizziness or balance problems. Patients often describe the pulsatile tinnitus as extremely bothersome—hearing their heartbeat constantly in their ear, unable to sleep in quiet rooms. Glomus vagale tumors along the vagus nerve cause hoarseness (most common), difficulty swallowing, shoulder weakness, and visible neck mass.
Sympathetic paragangliomas in the chest, abdomen, or pelvis often produce catecholamines—the same adrenaline hormones made by pheochromocytomas. About 40-60% of sympathetic paragangliomas are functional (hormone-producing) causing episodic attacks of severe headache, profuse sweating, rapid pounding heartbeat, pale face, trembling or shaking, chest or abdominal pain, anxiety or panic feeling, and very high blood pressure (often over 200/120 during attacks). These attacks happen suddenly, last minutes to hours, and leave patients exhausted afterward. Between attacks, patients may feel completely normal or have persistent high blood pressure. The symptoms are identical to pheochromocytoma—only the tumor location differs.
Some paragangliomas are discovered incidentally when patients undergo imaging for unrelated reasons—a neck CT for trauma might reveal an unsuspected carotid body tumor, or a chest X-ray for pneumonia might show a mediastinal paraganglioma. These asymptomatic tumors still require treatment because they continue growing, eventually causing symptoms and becoming more difficult to remove surgically.
Diagnosis Requires Imaging and Sometimes Hormone Testing
Diagnosing paraganglioma involves first suspecting it based on symptoms and location, then confirming with imaging and laboratory tests. For head and neck paragangliomas, imaging is the key diagnostic tool. CT scan with contrast shows a highly vascular mass (tumor lights up brightly when contrast dye is injected) in characteristic locations—carotid bifurcation, jugular foramen, middle ear, or along the vagus nerve. The “salt and pepper” appearance (speckled bright and dark areas) on MRI is highly suggestive of paraganglioma. Angiography (X-ray imaging of blood vessels) shows the tumor’s blood supply—critical information for surgical planning showing which arteries feed the tumor and whether major vessels are encased by tumor.
For suspected sympathetic paragangliomas or any paraganglioma where hormone production is suspected, biochemical testing measures catecholamines. The 24-hour urine collection measuring metanephrines and catecholamines is the most reliable test—patients collect all urine over 24 hours, and the laboratory measures hormone breakdown products. Elevated levels more than 2-3 times normal indicate a functional tumor. Blood tests measuring plasma free metanephrines are equally accurate and more convenient. Patients must avoid caffeine, certain medications, and stress before testing to prevent false positive results.
Once biochemical or imaging tests suggest paraganglioma, a special nuclear medicine scan called Ga-68 DOTATATE PET/CT or I-123 MIBG scan helps locate all tumor sites. These scans use radioactive tracers specifically taken up by neuroendocrine tumor cells, lighting up paragangliomas throughout the body. This is crucial because 10-20% of patients have multiple tumors—finding all of them before surgery prevents leaving tumors behind. The scans also detect metastases if the tumor has spread to lymph nodes, bones, liver, or lungs.
Genetic testing is extremely important because 40% of all paragangliomas are hereditary—the highest percentage of any tumor type. Even patients with no family history should undergo genetic testing because 25-30% carry new mutations not inherited from parents. Several genetic syndromes cause paragangliomas. Hereditary paraganglioma-pheochromocytoma syndromes caused by SDH gene mutations (SDHB, SDHD, SDHC, SDHAF2) account for 30-40% of hereditary cases and increase risk of multiple tumors, earlier age at diagnosis, and higher malignancy rates especially SDHB. Von Hippel-Lindau disease (VHL gene) causes paragangliomas plus kidney cysts, pancreatic tumors, and retinal tumors. Multiple Endocrine Neoplasia type 2 (MEN2, RET gene) causes paragangliomas plus thyroid cancer and parathyroid tumors. Neurofibromatosis type 1 (NF1 gene) causes paragangliomas plus café-au-lait skin spots and nerve tumors.
Treatment: Surgery Is the Main Option
Surgery is the primary treatment for most paragangliomas, aiming to completely remove the tumor while preserving critical nerves and blood vessels. However, paraganglioma surgery is among the most challenging in medicine because these tumors grow intimately around major arteries (carotid, vertebral), veins (jugular), and nerves (vagus, facial, glossopharyngeal, hypoglossal). Removing the tumor without causing stroke, major bleeding, or permanent nerve damage requires exceptional surgical skill.
For head and neck paragangliomas, surgical approach depends on location and size. Carotid body tumors are removed through a neck incision, carefully dissecting the tumor off the carotid artery. Small tumors can usually be removed completely preserving the artery. Large tumors wrapped around the artery may require removing a segment of artery and replacing it with a vein graft from the leg. Glomus jugulare and glomus tympanicum tumors require skull base surgery—working through the bone at the base of the skull and inner ear. This highly specialized surgery takes 6-12 hours and carries risks of hearing loss, facial nerve weakness, difficulty swallowing, and cerebrospinal fluid leak. Some surgeons perform preoperative embolization 24-48 hours before surgery—threading a catheter through blood vessels and blocking the arteries feeding the tumor with tiny particles. This reduces blood loss during surgery, making tumor removal safer.
For sympathetic paragangliomas that produce hormones, medical preparation before surgery is essential—identical to pheochromocytoma treatment. Patients take alpha-blockers (phenoxybenzamine or doxazosin) for 1-2 weeks before surgery blocking the effects of adrenaline and preventing dangerous blood pressure spikes when the tumor is manipulated. Beta-blockers are added controlling heart rate. High-salt diet and increased fluids expand blood volume preventing blood pressure crashes after tumor removal. During surgery, the anesthesiologist monitors blood pressure and heart rate continuously, giving medications to control extreme fluctuations.
After successful surgery, most patients experience excellent outcomes. Carotid body tumor removal: 95% complete removal, <5% stroke risk in experienced hands, possible temporary hoarseness or swallowing difficulty usually resolving within weeks. Glomus jugulare/tympanicum removal: hearing loss common if tumor involves the ear (often already present before surgery), facial nerve weakness 10-30% but usually temporary, long-term swallowing problems rare. For functional paragangliomas, hormone levels normalize within days after tumor removal, blood pressure returns to normal in most patients.
For malignant paragangliomas with metastases or tumors in locations too dangerous to remove surgically, alternative treatments include radiation therapy using stereotactic radiosurgery delivering focused high-dose radiation to the tumor causing it to stop growing or shrink, peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTATATE—radioactive medication that binds to tumor cells delivering internal radiation, chemotherapy with cyclophosphamide, vincristine, and dacarbazine for rapidly growing metastatic disease, and targeted therapy with sunitinib or other drugs blocking tumor blood vessel growth.
Living with Paraganglioma: Surveillance and Family Screening
After successful treatment, lifelong surveillance is necessary because paragangliomas can recur in 10-20% of patients, new tumors can develop especially in hereditary cases, and malignant tumors can metastasize years after initial treatment. Surveillance includes imaging (MRI or CT) of the original tumor site annually for 5 years, then every 2-3 years. Functional imaging with Ga-68 DOTATATE PET/CT every 2-3 years detects new tumors or metastases throughout the body. For functional tumors, annual biochemical testing (urine or blood metanephrines) identifies recurrence before symptoms develop.
Patients with hereditary syndromes require more intensive surveillance screening for multiple tumors. SDHB mutation carriers need annual biochemical testing, whole-body imaging every 1-2 years detecting paragangliomas anywhere from skull base to pelvis, kidney ultrasound or MRI every 2 years (increased kidney cancer risk), and consideration for prophylactic surgery if multiple tumors develop. VHL patients need kidney and pancreas imaging annually, retinal examination annually, and brain/spine MRI every 2 years. Family members of patients with hereditary syndromes should undergo genetic testing. If they carry the mutation, they need the same surveillance even without symptoms because early detection dramatically improves outcomes.
Overall prognosis for benign paragangliomas is excellent—complete surgical removal cures 90-95% of patients. Even patients unable to undergo complete resection often live many years with stable disease using radiation therapy or observation. Malignant paragangliomas have more variable outcomes—5-year survival rate 40-75% depending on extent of metastases, tumor growth rate, and response to treatment. SDHB-associated tumors have higher malignancy rates and worse prognosis than other genetic types. However, even metastatic paragangliomas often grow slowly—patients survive 10-20+ years with treatment managing their disease as a chronic condition.
Frequently Asked Questions
Q1: If paragangliomas are so rare, how would a regular doctor know to look for them?
You’re right that paragangliomas are rare, so many general doctors might not consider them immediately. However, certain “red flag” symptoms should trigger suspicion. A pulsatile neck mass (you can feel it throbbing with your heartbeat) is highly suspicious for carotid body paraganglioma—most lumps in the neck are lymph nodes or cysts that don’t pulsate. Pulsatile tinnitus (hearing your heartbeat in your ear) in a young adult strongly suggests glomus tumor—this is different from the steady ringing of common tinnitus. Anyone under 40 with high blood pressure and episodic symptoms (headaches, sweating, rapid heartbeat) should be screened for pheochromocytoma/paraganglioma—high blood pressure in young people has identifiable causes unlike older adults where it’s often “essential hypertension.” Family history of these tumors or associated genetic syndromes (VHL, MEN2, neurofibromatosis) should prompt screening even without symptoms. When doctors encounter these red flags, they typically refer patients to specialists—endocrinologists for functional tumors, head-neck surgeons or neurosurgeons for head-neck paragangliomas—who have more experience with these rare conditions. The key is that patients shouldn’t ignore unusual symptoms like pulsatile tinnitus, pulsating neck masses, or episodic attacks assuming they’ll go away. Bringing these symptoms to medical attention persistently, seeing specialists if your regular doctor is uncertain, ensures proper diagnosis.
Q2: Can children get paragangliomas or are they only in adults?
Children can definitely develop paragangliomas, though they’re less common than in adults. About 10-15% of all paragangliomas occur before age 18, with cases reported as young as age 3-4 years. When paragangliomas occur in children, they’re almost always hereditary—studies show 70-90% of pediatric cases have genetic mutations compared to 40% overall. The most common genetic cause in children is SDH gene mutations, particularly SDHB and SDHD. This means any child diagnosed with paraganglioma should undergo comprehensive genetic testing, and all family members should be screened. Children with hereditary syndromes often develop multiple tumors—bilateral carotid body paragangliomas, or paragangliomas in both the neck and abdomen simultaneously. Symptoms in children are similar to adults—neck masses, pulsatile tinnitus, high blood pressure attacks—but younger children may not describe symptoms clearly, making diagnosis more challenging. Treatment is the same as adults—surgical removal when possible—but pediatric cases require extra caution preserving growth plates, avoiding radiation when possible (higher lifetime cancer risk), and planning for decades of surveillance. Prognosis is generally excellent in children with benign tumors, though the hereditary nature means lifelong vigilance for new tumors. Starting surveillance early allows detection of subsequent tumors when small and easier to remove.
Q3: What is the difference between “observation” and “active surveillance” for paragangliomas? When would a doctor recommend not removing the tumor?
Great question about an important distinction. “Active surveillance” means deliberately choosing not to remove a paraganglioma immediately but monitoring it closely with regular imaging, ready to intervene if it grows or causes problems. This is different from “watchful waiting” where less intensive monitoring occurs. Doctors recommend active surveillance for specific situations: very elderly patients (age 75-80+) with small asymptomatic tumors—surgery risks may outweigh benefits given limited life expectancy and slow tumor growth. Small glomus tympanicum tumors causing minimal symptoms in older adults—hearing is already reduced, surgery might worsen it. Multiple small paragangliomas in patients with hereditary syndromes—removing every small tumor would require multiple surgeries potentially causing more disability than the tumors themselves. Tumors in surgically inaccessible locations (like deep skull base) that are stable and asymptomatic. During active surveillance, patients undergo MRI or CT imaging every 6-12 months initially, then annually if stable. Any growth >2-3mm per year, new symptoms, or patient preference triggers treatment—usually surgery or radiation therapy. The vast majority of head and neck paragangliomas grow very slowly—studies show average growth 0.8-2mm per year. Some remain stable for years without treatment. However, functional paragangliomas producing hormones should almost always be removed because chronic catecholamine excess damages the heart, blood vessels, and kidneys even without symptoms. Similarly, young patients with surgically accessible tumors usually undergo removal because the tumors will eventually grow causing problems, and surgery is safer when tumors are smaller. Active surveillance is a reasonable option in select cases, but it requires committed patients who will attend all follow-up appointments and specialists experienced in managing these rare tumors.
Q4: If paragangliomas are hereditary, does that mean my children will definitely get them?
Hereditary paragangliomas follow autosomal dominant inheritance, meaning if you carry a genetic mutation, each of your children has a 50% chance of inheriting that mutation. However, inheriting the mutation does not guarantee developing tumors—the concept called “incomplete penetrance.” For example, SDHD mutations have 90% penetrance by age 70—meaning 90% of mutation carriers develop tumors during their lifetime, but 10% never do despite carrying the mutation. SDHB has lower penetrance around 40-50%. Additionally, the age when tumors develop varies widely—some mutation carriers develop tumors in their teens or twenties, others not until their fifties or sixties. Your children who inherit the mutation need lifelong surveillance but may never develop tumors, or might develop tumors much later in life when treatment options are better. For children who don’t inherit the mutation, their risk is the same as the general population (essentially zero). Genetic testing of your children can be done after age 5-10 years (timing depends on the specific syndrome) to determine who inherited the mutation and needs surveillance versus who can be reassured they won’t develop hereditary tumors. This eliminates uncertainty, focuses surveillance on those who need it, and spares non-carriers unnecessary testing and anxiety. Some parents choose to test children early; others wait until the child is old enough to participate in the decision. Genetic counselors help families navigate these decisions. The important message is that hereditary doesn’t mean inevitable—surveillance allows early detection when tumors are small and most treatable, and many mutation carriers live long healthy lives even if they develop tumors because modern treatment is so effective.
Q5: Can paragangliomas ever shrink or go away on their own without treatment?
Unfortunately, spontaneous regression (tumors shrinking or disappearing without treatment) essentially never occurs with paragangliomas. Unlike some pediatric cancers like neuroblastoma where spontaneous regression is documented, paragangliomas have persistent growth patterns. Once they develop, they continue enlarging—though growth rates vary tremendously. Head and neck paragangliomas typically grow very slowly averaging 0.8-2mm per year, meaning a 1cm tumor might take 5-10 years to double in size. This slow growth explains why active surveillance is sometimes feasible in elderly patients or those with multiple tumors. Sympathetic paragangliomas tend to grow faster, and malignant paragangliomas can grow quite rapidly doubling in months. Importantly, paragangliomas producing hormones continue doing so—they won’t spontaneously stop hormone production, so symptoms persist or worsen until the tumor is removed. There are extremely rare reports of tumor stabilization during pregnancy (thought related to hormonal changes) but tumors resume growing after delivery, so this isn’t true regression. Some very old case reports describe “calcified carotid body tumors” that supposedly stopped growing and calcified in place, but modern pathology reviews suggest many of these were misdiagnosed—they were probably atherosclerotic plaques or other conditions rather than true paragangliomas. Bottom line: if you have a confirmed paraganglioma, don’t wait hoping it will shrink. It won’t. The question is timing of treatment—immediate versus observation with planned intervention if growth occurs—but eventually, treatment (surgery or radiation) will be needed. The good news is that modern treatment is highly effective, so early detection and appropriate timing of intervention leads to excellent outcomes for the vast majority of patients.
Disclaimer
This article adapts publicly available information from medical databases and research organizations. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform — not a healthcare provider. Decisions about paraganglioma screening, diagnosis, and treatment should be made in consultation with qualified physicians, endocrinologists, head and neck surgeons, neurosurgeons, and genetic counselors who can evaluate your individual symptoms, imaging findings, genetic testing results, and health circumstances. If you have a neck mass, pulsatile tinnitus, hearing loss, or symptoms of hormone excess, please consult with your healthcare team immediately.
References
- National Cancer Institute. Pheochromocytoma and Paraganglioma Treatment. https://www.cancer.gov/types/pheochromocytoma/patient/pheochromocytoma-treatment-pdq
- PMC. Hereditary Paraganglioma-Pheochromocytoma Syndromes. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210907/
- PMC. Clinical Presentation and Management of Paragangliomas. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463224/
- Johns Hopkins Medicine. Paraganglioma and Glomus Tumors. https://www.hopkinsmedicine.org/health/conditions-and-diseases/paraganglioma
- World Health Organization. Cancer Topics. https://www.who.int/health-topics/cancer
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
